The Thailand next generation sequencing market is projected to reach $305.21 million by 2036, at a CAGR of 12.7% from 2026 to 2036, up from an estimated $92.03 million in 2026. The market was valued at $80.03 million in 2025 and $70.20 million in 2024. The growth of this market is primarily fueled by the continued expansion of Genomics Thailand and the national precision medicine agenda, increasing clinical adoption in oncology and rare diseases, and the growth of outsourced sequencing services. Additionally, widening reimbursement coverage under the Universal Coverage Scheme - including the recent addition of BRCA1 and BRCA2 testing for high-risk breast cancer patients and their family members - and early-stage integration of sequencing with multiomics and advanced bioinformatics are expected to create substantial growth opportunities for market participants.
Genomics Thailand, launched in 2019 as a five-year initiative under the Thailand 4.0 strategic agenda, set out to sequence 50,000 Thai genomes across five disease areas through a consortium of more than 40 national agencies, institutes, medical schools, and hospitals, with the first phase reaching completion during 2025 and a stated intention to expand toward 100,000 samples. More than 180,000 new cancer cases were diagnosed in Thailand in 2022 according to GLOBOCAN, with IARC Cancer Tomorrow projections indicating roughly 50% growth in annual incidence by 2045. Approximately 30 to 40% of Thai individuals, an estimated 18 to 24 million people, carry thalassemia or another haemoglobin disorder, with more than 12,000 infants born with thalassemia each year, according to Thailand's Ministry of Public Health.
The key players operating in the Thailand next generation sequencing market are Illumina, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), QIAGEN N.V. (Netherlands), Agilent Technologies, Inc. (U.S.), F. Hoffmann La Roche Ltd. (Switzerland), Revvity, Inc. (U.S.), Pacific Biosciences of California, Inc. (U.S.), Oxford Nanopore Technologies plc (U.K.), MGI Tech Co., Ltd. (China), Bangkok Genomics Innovation Public Company Limited (Thailand), Eurofins Scientific SE (Luxembourg), Novogene Co., Ltd. (China), and Next Generation Genomic Co., Ltd. (Thailand).
The Thailand next generation sequencing market study presents historical market data value (2024, 2025), estimated current data (2026), and forecasts for 2036. This market is segmented by offering, application, and end user.
Among all the offerings, Commercial Sequencing/Outsourced Services account for the largest share of the market in 2026, supported by the outsourcing structure under which institutions purchase sequencing as a completed service rather than establishing capability they cannot keep occupied. This same segment is also projected to register the fastest growth through 2036, driven by the migration of genomic testing into reimbursed clinical pathways.
Among all the applications, Research & Other Applications hold the larger share of the market in 2026, driven by the funding structure through which Thai sequencing capacity was established under Genomics Thailand. Clinical Applications, however, is expected to register the faster growth and to overtake research applications in absolute value before the end of the forecast period, driven by the migration of genomic testing from research protocols into reimbursed diagnostic pathways. Within clinical applications, oncology holds the largest share and the fastest growth, while reproductive health accounts for the largest share by test volume owing to Thailand's long-established national thalassaemia prevention and control program.
Among all the end users, Hospitals & Diagnostic Laboratories account for the largest share of the market in 2026 and are projected to register the fastest growth, driven by the attribution convention under which market value is recorded against the institution whose requirement generates the demand. Academic & Research Institutes hold the largest share of the sequencing capacity actually installed in the country, since the high-throughput capacity required by Genomics Thailand was installed at academic and national research sites, yet rank second by market value in 2026.
Clinical and academic genomics capability in Thailand is concentrated in a limited number of institutions, principally the medical faculties of Chulalongkorn, Mahidol, and Khon Kaen universities and their affiliated teaching hospitals, together with the National Science and Technology Development Agency and high-throughput sequencing platforms sited at Burapha University within the Eastern Economic Corridor.
Genomics Thailand, launched in 2019 as a five-year initiative under the Thailand 4.0 strategic agenda, set out to sequence 50,000 Thai genomes across five disease areas through a consortium of more than 40 national agencies, institutes, medical schools, and hospitals, with the first phase reaching completion during 2025 and a stated intention to expand toward 100,000 samples. More than 180,000 new cancer cases were diagnosed in Thailand in 2022 according to GLOBOCAN, with IARC Cancer Tomorrow projections indicating roughly 50% growth in annual incidence by 2045. Approximately 30 to 40% of Thai individuals, an estimated 18 to 24 million people, carry thalassemia or another haemoglobin disorder, with more than 12,000 infants born with thalassemia each year, according to Thailand's Ministry of Public Health.
The key players operating in the Thailand next generation sequencing market are Illumina, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), QIAGEN N.V. (Netherlands), Agilent Technologies, Inc. (U.S.), F. Hoffmann La Roche Ltd. (Switzerland), Revvity, Inc. (U.S.), Pacific Biosciences of California, Inc. (U.S.), Oxford Nanopore Technologies plc (U.K.), MGI Tech Co., Ltd. (China), Bangkok Genomics Innovation Public Company Limited (Thailand), Eurofins Scientific SE (Luxembourg), Novogene Co., Ltd. (China), and Next Generation Genomic Co., Ltd. (Thailand).
The Thailand next generation sequencing market study presents historical market data value (2024, 2025), estimated current data (2026), and forecasts for 2036. This market is segmented by offering, application, and end user.
Among all the offerings, Commercial Sequencing/Outsourced Services account for the largest share of the market in 2026, supported by the outsourcing structure under which institutions purchase sequencing as a completed service rather than establishing capability they cannot keep occupied. This same segment is also projected to register the fastest growth through 2036, driven by the migration of genomic testing into reimbursed clinical pathways.
Among all the applications, Research & Other Applications hold the larger share of the market in 2026, driven by the funding structure through which Thai sequencing capacity was established under Genomics Thailand. Clinical Applications, however, is expected to register the faster growth and to overtake research applications in absolute value before the end of the forecast period, driven by the migration of genomic testing from research protocols into reimbursed diagnostic pathways. Within clinical applications, oncology holds the largest share and the fastest growth, while reproductive health accounts for the largest share by test volume owing to Thailand's long-established national thalassaemia prevention and control program.
Among all the end users, Hospitals & Diagnostic Laboratories account for the largest share of the market in 2026 and are projected to register the fastest growth, driven by the attribution convention under which market value is recorded against the institution whose requirement generates the demand. Academic & Research Institutes hold the largest share of the sequencing capacity actually installed in the country, since the high-throughput capacity required by Genomics Thailand was installed at academic and national research sites, yet rank second by market value in 2026.
Clinical and academic genomics capability in Thailand is concentrated in a limited number of institutions, principally the medical faculties of Chulalongkorn, Mahidol, and Khon Kaen universities and their affiliated teaching hospitals, together with the National Science and Technology Development Agency and high-throughput sequencing platforms sited at Burapha University within the Eastern Economic Corridor.
Key Questions Answered in the Report:
- What is the current revenue generated by the Thailand next generation sequencing market?
- At what rate is the Thailand NGS market demand projected to grow through 2036?
- What are the historical market sizes and growth rates of the Thailand NGS market?
- What are the major factors impacting the growth of this market? What are the major opportunities for existing players and new entrants in the market?
- Which segments in terms of offering, application, and end user are expected to create major traction for the manufacturers in this market?
- Who are the major players in the Thailand NGS market? What are their specific product offerings in this market?
- What are the recent strategic developments in the Thailand NGS market? What are the impacts of these strategic developments on the market?
Table of Contents
1. Market Definition & Scope
2. Research Methodology
4. Market Insights
5. Thailand NGS Market Assessment — By Offering
6. Thailand NGS Market Assessment — By Application
7. Thailand NGS Market Assessment — By End User
8. Competitive Landscape
9. Company Profiles
10. 10. Appendix
LIST OF TABLES
LIST OF FIGURES
Companies Mentioned
- Illumina, Inc.
- Thermo Fisher Scientific Inc.
- QIAGEN N.V.
- Agilent Technologies, Inc.
- F. Hoffmann La Roche Ltd.
- Revvity, Inc.
- Pacific Biosciences of California, Inc.
- Oxford Nanopore Technologies plc
- MGI Tech Co., Ltd.
- Bangkok Genomics Innovation Public Company Limited
- Eurofins Scientific SE
- Novogene Co., Ltd.
- Next Generation Genomic Co., Ltd. (Thailand).
